Nogueira-Rodrigues A, Melo AC, Werutsky G, Garces AH, Ferreira CG.Curr Cancer Drug Targets. 2015 Nov 17. Full link: https://www.ncbi.nlm.nih.gov/m/pubmed/26577537/
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotoxic drugs, are warranted.
Martínez-Mesa J, Werutsky G, Campani RB, Wehrmeister FC, Barrios CH. Prev Med. 2013 Oct;57(4):366-71 Full link: https://www.thelancet.com/commissions/latin-america
Impact of Regulatory Delays in Drug Approval: Mortality and Morbidity Due to With Lack of Access to Crizotinib in Brazil
Pablo Moura Barrios, Marcio Debiasi, Gilberto Lopes, Carlos H. BarriosOctober 2016 Volume 11, Issue 10, Supplement, Page S215 Full link: https://www.jto.org/article/S1556-0864(16)30782-1/fulltext
Carlos H. Barrios, MD, Gustavo Werutsky, MD, and Jeovany Martinez-Mesa, MD, PhDAm Soc Clin Oncol Educ Book. 2015:e132-9 Full link: http://meetinglibrary.asco.org/content/11500132-156